




CONTACT SHEBA MEDICAL CENTER

 +972-77-997-2480

GLOBAL PATIENT SERVICES AT SHEBA

[Our 360 Degree Approach](#)

[Global Patient Services](#)

[Why Sheba?](#)

[Benefits of Treatment at Sheba](#)

[Meet the Team](#)

[Patient Stories](#)

USEFUL INFORMATION

[Find a Doctor](#)

[The Cancer Center](#)

[The Rehabilitation Hospital](#)

[The Children's Hospital](#)

[Hemato-Oncology Division](#)

[News](#)

[General Health Articles](#)

[Authorized Representative](#)

[Collaborating with Sheba](#)

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit [Cookie Settings](#) to provide a controlled con

[Cookie settings](#)

[ACCEPT](#)






According to a study conducted by Sheba Medical Center and the Israeli Ministry of Health, three doses of the Pfizer-BioNTech COVID-19 vaccine provide significant protection against the Omicron variant.

Following the emergence of the COVID-19 Omicron variant, many wondered if existing vaccines

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled con

[Cookie settings](#)

[ACCEPT](#)



REQUEST A CONSULTATION



In contrast, the study found that two doses of the vaccine are not likely to be effective against the Omicron variant. Thus, an individual vaccinated only twice remains at high risk of contracting the variant and becoming seriously ill.

According to Prof. Gili Regev-Yochay, Head of the Infection Prevention and Control Unit at Sheba, who also led the study: "The findings emphasized the importance of increasing the vaccination rates as an effective and necessary measure to stop the spread of the virus."

[< Previous](#)

[Next >](#)

Related



We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit [Cookie Settings](#) to provide a controlled con

[Cookie settings](#)

[ACCEPT](#)



REQUEST A CONSULTATION



Tel HaShomer | Patient Services

PLATFORM

A groundbreaking gestational diabetes pilot was recently completed by the two organizations, deploying Nuvo's INVU platform at Sheba's Beyond Virtual Hospital, simplifying care for pregnant...

[Read More](#)

CANCER PATIENTS

Pancreatic cancer, the 12th most common cancer worldwide, is associated with pain in approximately 75% of patients at the time of diagnosis, and as much...

[Read More](#)

Lung cancer is the most common cancer and accounts for 1.76 million deaths per year worldwide. Non-small cell lung cancer (NSCLC) comprises 85% of all...

[Read More](#)

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit [Cookie Settings](#) to provide a controlled con

[Cookie settings](#)

[ACCEPT](#)

